CLEC9A hFc Chimera, Mouse
CLEC9A HFc Chimera, Mouse

The purity of CLEC9A hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

CLEC9A HFc Chimera, Mouse

CLEC9A hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC9A hFc Chimera, Mouse

CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
Z06066
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
hFc CLEC9A (Lys57-Ile264)_x000D_
Accession # NP_001192292.1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 50.9 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • CLEC9A HFc Chimera, Mouse
    • CLEC9A HFc Chimera, Mouse

    The purity of CLEC9A hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

  • CLEC9A HFc Chimera, Mouse
    • CLEC9A HFc Chimera, Mouse

    CLEC9A hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background CLEC9A is a recently discovered C-type lectin receptor involved in sensing necrotic cells. In humans, this receptor is selectively expressed by BDCA3(+) myeloid dendritic cells (mDCs), which have been proposed to be the main human cross-presenting mDCs and may represent the human homologue of murine CD8(+) DCs. In mice, it was demonstrated that antigens delivered with antibodies to CLEC9A are presented by CD8(+) DCs to both CD4(+) and CD8(+) T cells and induce antitumor immunity in a melanoma model.
Synonyms CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.